Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Rainier Therapeutics
San Ramon, California, United Statesrainiertx.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
BioClin’s lead asset was B-701 (later called vofatamab), a first-in-class human monoclonal antibody targeting FGFR3. It advanced through Phase 1b and Phase 2 studies in metastatic urothelial carcinoma/bladder cancer—both as monotherapy and in combination with docetaxel or immunotherapies like atezolizumab and pembrolizumab. Early results showed promise especially for patients with FGFR3 mutations or overexpression. The company also explored preclinical work on achondroplasia.
- Therapeutic areas
- Rare DiseasesOncology
- Modalities
- Monoclonal antibodyBiologic
- Industry
- Biotech
02
Partnerships
Clinical collaborations using Roche’s atezolizumabClinical collaborations using Merck’s pembrolizumab
Beyond the preview
Go deeper on Rainier Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Rainier Therapeutics.